AST

Bilander Acquisition Corp. Announces Redemption of Class A Common Stock

Retrieved on: 
Wednesday, July 19, 2023
Other Professional Services, Professional Services, Finance, Transfer, Common stock, United States Army Acquisition Corps, Tax, Trust, Bangladesh Securities and Exchange Commission, Accounting, Wind, Interest on Lawyer Trust Accounts, AST, Common, Security (finance)

Net of taxes and dissolution expenses, the per-share redemption price for the Class A Common Stock is expected to be approximately $10.25 (the “Redemption Amount”).

Key Points: 
  • Net of taxes and dissolution expenses, the per-share redemption price for the Class A Common Stock is expected to be approximately $10.25 (the “Redemption Amount”).
  • As of July 26, 2023, the Class A Common Stock will be deemed cancelled and will represent only the right to receive the Redemption Amount.
  • The Company’s initial stockholders waived their redemption rights with respect to the outstanding Class B common stock issued prior to the Company’s initial public offering.
  • The redemption of the Class A Common Stock is expected to be completed within ten business days after July 20, 2023.

ASTS ALERT: Levi & Korsinsky, LLP Announces an Investigation into the Fairness of AST SpaceMobile Inc.'s De-SPAC Merger

Retrieved on: 
Tuesday, July 18, 2023
Person, Telephone, LLP, Levi, AST, ASTS

You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of ASTS' 2021 de-SPAC merger.

Key Points: 
  • You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of ASTS' 2021 de-SPAC merger.
  • To learn more about the action and your rights, go to:
    or contact Joseph E. Levi, Esq.
  • The ASTS de-SPAC merger investigation concerns whether this transaction unfairly harmed stockholders and whether all material facts were properly disclosed to stockholders.
  • Levi & Korsinsky is a nationally recognized firm with offices in New York, Connecticut, California, and Washington, D.C.

Tenneco OE Suspension Plant in Changzhou, China, Marks Five Years of Consecutive Growth

Retrieved on: 
Tuesday, July 18, 2023
VW, Partnership, Geely, Mercedes-Benz, OE, Audi, Monroe, Growth, Volkswagen Group, AST, General Motors, Li Auto, Bridge, Renewable energy, Automotive industry, Tenneco

NORTHVILLE, Ill., July 18, 2023 (GLOBE NEWSWIRE) -- The Tenneco suspension business recently celebrated five years of consecutive growth of Monroe®-branded OE suspension products at its Changzhou, China, manufacturing facility.

Key Points: 
  • NORTHVILLE, Ill., July 18, 2023 (GLOBE NEWSWIRE) -- The Tenneco suspension business recently celebrated five years of consecutive growth of Monroe®-branded OE suspension products at its Changzhou, China, manufacturing facility.
  • Today the Changzhou plant is one of the country’s largest automotive damper manufacturing sites, with 900 team members and a combined annual capacity of 18 million Monroe® OE Solutions passive dampers and Monroe Intelligent Suspension CVSAe electronic dampers.
  • In May, the Changzhou plant produced its 1 millionth CVSAe electronic damper, underscoring the strengthening position of Monroe Intelligent Suspension technology in the world’s largest and fastest growing automotive market.
  • Additional information regarding Monroe OE Solutions passive suspension products can be found here .

Miromatrix Poster Voted Best in Congress at the 2023 American Transplant Congress; Jack Lake Wins Lifetime Achievement Award

Retrieved on: 
Thursday, July 13, 2023
Society, Transplant, American Society of Transplantation, Congress, Patient, Kidney, Poster, EDEN, ATC, AST, MIRO, Pharmaceutical industry, Dentistry, MD

"We appreciate the opportunity to present our kidney work at ATC, and it was an honor to receive the Best in Congress acknowledgment," said Jeff Ross, Ph.D., Miromatrix CEO.

Key Points: 
  • "We appreciate the opportunity to present our kidney work at ATC, and it was an honor to receive the Best in Congress acknowledgment," said Jeff Ross, Ph.D., Miromatrix CEO.
  • "Thanks to our talented team of scientists, including David Lo, for advancing our work to someday provide new options to the thousands of patients who need a kidney transplant."
  • Also at ATC, Jack Lake, MD, Miromatrix Medical Director, received the American Society of Transplantation's (AST) 2023 Lifetime Achievement Award.
  • The award - the Society's highest honor – recognizes Dr. Lake's outstanding achievements and contributions to the AST and the field of transplantation.

STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of AST SpaceMobile, Inc. and Encourages Long-Term ASTS / NPA Investors to Contact the Firm

Retrieved on: 
Monday, July 10, 2023
SPAC, AST SpaceMobile, NPA, Acquisition, AST, ASTS, Cryptocurrency, Financial adviser

PHILADELPHIA, July 10, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating AST SpaceMobile, Inc. (NASDAQ: ASTS) (“AST SpaceMobile”) on behalf of the company’s long-term investors.

Key Points: 
  • PHILADELPHIA, July 10, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating AST SpaceMobile, Inc. (NASDAQ: ASTS) (“AST SpaceMobile”) on behalf of the company’s long-term investors.
  • Following the announcement of the proposed SPAC transaction, shares of AST SpaceMobile traded as high as $20.00 per share in February 2021.
  • AST SpaceMobile investors who purchased or acquired shares of ASTS / NPA stock prior to March 1, 2021 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.
  • Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation.

Care Partner Mobile Application Launch Party

Retrieved on: 
Friday, July 7, 2023
Caregiver, Education, Dementia, Research, Alzheimer Society of Ontario, Mount Sinai Hospital, Eglinton Avenue, Apple, AST, Residential care

Toronto, July 07, 2023 (GLOBE NEWSWIRE) -- On July 7th, the Alzheimer Society of Toronto will launch the Care Partner Mobile Application on both the Apple and Google Play stores with a launch party.

Key Points: 
  • Toronto, July 07, 2023 (GLOBE NEWSWIRE) -- On July 7th, the Alzheimer Society of Toronto will launch the Care Partner Mobile Application on both the Apple and Google Play stores with a launch party.
  • The Care Partner App, previously known as the Dementia Talk App – is an award-winning mobile application created by the Reitman Centre at Mount Sinai Hospital.
  • The Care Partner mobile application uses tools and resources to support the caregiver of someone living with dementia, with the goal of promoting everyone's wellbeing.
  • Caregivers or care partners of people living with dementia are invited to attend the launch party which will be held from 10 am – 12 pm at the Alzheimer Society of Toronto office at 20 Eglinton Avenue West, on the 16th floor.

Satellite Technology and Cellular Smartphone Convergence Propel 5G NTN-Mobile Market to US$18 Billion in Service Revenues by 2031

Retrieved on: 
Thursday, July 6, 2023
AT&T, Communications satellite, Communication, Bell Canada, Huawei, AT, Smartphone, NTN, Cavalier, Telephone, Human, ZTE, Research, STC, Globalstar, Inmarsat, Compound annual growth rate, Motorola, MNO, Monolithic kernel, MTN Group, Apple, AST SpaceMobile, SpaceX, Growth, Role, 3GPP, Saudi Telecom Company, MediaTek, T-Mobile, AST, Rakuten Mobile Park Miyagi, Mobile phone, Iridium, Qualcomm, Lynk, Vodafone

Following the release of 3GPP Release-17, the satellite-to-mobile marketplace has gained significant momentum, driven by notable product launches and major announcements.

Key Points: 
  • Following the release of 3GPP Release-17, the satellite-to-mobile marketplace has gained significant momentum, driven by notable product launches and major announcements.
  • Companies such as Apple , Huawei , ZTE , Qualcomm , Motorola , MediaTek , Bullitt , Globalstar , Inmarsat , and Iridium , among others have formed strategic partnerships within the cellular mobile and satellite industries.
  • T-Mobile , a United States-based MNO, for instance, has partnered with satellite operator SpaceX /Starlink to provide satellite-to-mobile connectivity services.
  • Based on extensive primary interviews, Application Analysis reports present in-depth analysis on key market trends and factors for a specific technology.

Satellite Technology and Cellular Smartphone Convergence Propel 5G NTN-Mobile Market to US$18 Billion in Service Revenues by 2031

Retrieved on: 
Thursday, July 6, 2023
AT&T, Communications satellite, Communication, Bell Canada, Huawei, AT, Smartphone, NTN, Cavalier, Telephone, Human, ZTE, Research, STC, Globalstar, Inmarsat, Compound annual growth rate, Motorola, MNO, Monolithic kernel, MTN Group, Apple, AST SpaceMobile, SpaceX, Growth, Role, 3GPP, Saudi Telecom Company, MediaTek, T-Mobile, AST, Rakuten Mobile Park Miyagi, Mobile phone, Iridium, Qualcomm, Lynk, Vodafone

Following the release of 3GPP Release-17, the satellite-to-mobile marketplace has gained significant momentum, driven by notable product launches and major announcements.

Key Points: 
  • Following the release of 3GPP Release-17, the satellite-to-mobile marketplace has gained significant momentum, driven by notable product launches and major announcements.
  • Companies such as Apple , Huawei , ZTE , Qualcomm , Motorola , MediaTek , Bullitt , Globalstar , Inmarsat , and Iridium , among others have formed strategic partnerships within the cellular mobile and satellite industries.
  • T-Mobile , a United States-based MNO, for instance, has partnered with satellite operator SpaceX /Starlink to provide satellite-to-mobile connectivity services.
  • Based on extensive primary interviews, Application Analysis reports present in-depth analysis on key market trends and factors for a specific technology.

Allied Motion Announces Robert P. Maida’s Retirement

Retrieved on: 
Friday, June 30, 2023
Automotive Manufacturing, Aerospace, Manufacturing, Other Technology, Technology, Senior, Social, Retirement, AMOT, Growth, AST, Allied Motion Technologies, Operational excellence, Management

Allied Motion Technologies Inc. (Nasdaq: AMOT) (“Allied Motion” or the “Company”), a designer and manufacturer of precision and specialty controlled motion products and solutions for the global market, announced today that Robert P. Maida, Senior Vice President and Group President, will retire September 30, 2023 after more than 10 years with the Company.

Key Points: 
  • Allied Motion Technologies Inc. (Nasdaq: AMOT) (“Allied Motion” or the “Company”), a designer and manufacturer of precision and specialty controlled motion products and solutions for the global market, announced today that Robert P. Maida, Senior Vice President and Group President, will retire September 30, 2023 after more than 10 years with the Company.
  • Upon his retirement, Mr. Maida will serve in an advisory role to the CEO.
  • Dick Warzala, Chairman and CEO, commented, “For more than a decade, Rob has been a great partner to me and has played an instrumental role in helping shape and build Allied into the global, controlled motion solution provider we are today.
  • Rob has held various key leadership positions and roles within Allied and perhaps most significantly, has always been recognized as a team player by all within the company.

New ropeginterferon alfa-2b Data Suggest Alternate Dosing Schedule May Achieve Greater and Quicker Complete Hematologic and Molecular Responses in Polycythemia Vera

Retrieved on: 
Friday, June 30, 2023
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, CHR, Ruxolitinib, Experimental Hematology, Polycythemia vera, Hydroxycarbamide, Ropeginterferon alfa-2b, Aes, PV, Trial of the century, HIV disease progression rates, Patient, Risk, ALT, Myeloproliferative neoplasm, Polycythemia, AST, MPN, Pharmaceutical industry

This study, which was conducted in China, demonstrated the efficacy and tolerability of ropeginterferon alfa-2b using an alternate dosing regimen that has a higher starting dose and a more rapid dose titration as compared to current U.S. label dosing.

Key Points: 
  • This study, which was conducted in China, demonstrated the efficacy and tolerability of ropeginterferon alfa-2b using an alternate dosing regimen that has a higher starting dose and a more rapid dose titration as compared to current U.S. label dosing.
  • The publication, titled “A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera,” was published in Experimental Hematology & Oncology and co-authored by PharmaEssentia researchers.
  • PV is the most common myeloproliferative neoplasm (MPN) and a long-term, potentially life-threatening disease with limited approved treatment options.
  • Long-term treatment and follow-up of the patients in the study are planned to assess progression-free and overall survival.